Literature DB >> 35969769

Endothelial VWF is critical for the pathogenesis of vaso-occlusive episode in a mouse model of sickle cell disease.

Huiping Shi1,2, Bojing Shao1, Liang Gao1, Thamizhiniyan Venkatesan1, John Michael McDaniel1, Meixiang Zhou1, Samuel McGee1, Pengchun Yu1, Jasimuddin Ahamed1, Janna Journeycake3, James N George4, Lijun Xia1,2.   

Abstract

Vaso-occlusive episode (VOE) is a common and critical complication of sickle cell disease (SCD). Its pathogenesis is incompletely understood. von Willebrand factor (VWF), a multimeric plasma hemostatic protein synthesized and secreted by endothelial cells and platelets, is increased during a VOE. However, whether and how VWF contributes to the pathogenesis of VOE is not fully understood. In this study, we found increased VWF levels during tumor necrosis factor (TNF)-induced VOE in a humanized mouse model of SCD. Deletion of endothelial VWF decreased hemolysis, vascular occlusion, and organ damage caused by TNF-induced VOE in SCD mice. Moreover, administering ADAMTS13, the VWF-cleaving plasma protease, reduced plasma VWF levels, decreased inflammation and vaso-occlusion, and alleviated organ damage during VOE. These data suggest that promoting VWF cleavage via ADAMTS13 may be an effective treatment for reducing hemolysis, inflammation, and vaso-occlusion during VOE.

Entities:  

Keywords:  sickle cell disease; vaso-occlusive episode; von Willebrand factor

Mesh:

Substances:

Year:  2022        PMID: 35969769      PMCID: PMC9407592          DOI: 10.1073/pnas.2207592119

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  35 in total

1.  P-selectin mediates the adhesion of sickle erythrocytes to the endothelium.

Authors:  N M Matsui; L Borsig; S D Rosen; M Yaghmai; A Varki; S H Embury
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

2.  GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.

Authors:  Jungshan Chang; John T Patton; Arun Sarkar; Beat Ernst; John L Magnani; Paul S Frenette
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

3.  Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease.

Authors:  Enrico M Novelli; Gregory J Kato; Mariana E Hildesheim; Suchitra Barge; Michael P Meyer; Jay Lozier; Andrea Cortese Hassett; Margaret V Ragni; Jeffrey S Isenberg; Mark T Gladwin
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

4.  A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Authors:  Andrew Yee; Robert D Gildersleeve; Shufang Gu; Colin A Kretz; Beth M McGee; Keisha M Carr; Steven W Pipe; David Ginsburg
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

5.  Kinetics of sickle cell biorheology and implications for painful vasoocclusive crisis.

Authors:  E Du; Monica Diez-Silva; Gregory J Kato; Ming Dao; Subra Suresh
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

Review 6.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2017-08-02       Impact factor: 22.113

7.  The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma.

Authors:  Junmei Chen; William E Hobbs; Jennie Le; Peter J Lenting; Philip G de Groot; José A López
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

8.  Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.

Authors:  J W R Sins; M Schimmel; B M Luken; E Nur; S S Zeerleder; C F J van Tuijn; D P M Brandjes; W F Kopatz; R T Urbanus; J C M Meijers; B J Biemond; K Fijnvandraat
Journal:  J Thromb Haemost       Date:  2017-06-05       Impact factor: 5.824

9.  Evidence of protective effects of recombinant ADAMTS13* in humanized model for sickle cell disease.

Authors:  Paolo Rossato; Enrica Federti; Alessandro Matte; Helmut Glantschnig; Fabio Canneva; Maria Schuster; Sogue Coulibaly; Gerald Schrenk; Dirk Voelkel; Michael Dockal; Barbara Plaimauer; Immacolata Andolfo; Achille Iolascon; Hanspeter Rottensteiner; Herbert Gritsch; Friedrich Scheiflinger; Werner Hoellriegl; Lucia De Franceschi
Journal:  Haematologica       Date:  2022-04-21       Impact factor: 9.941

10.  Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.

Authors:  H M Tsai
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

View more
  1 in total

1.  Altered VWF:ADAMTS13 homeostasis is a target for therapeutic intervention in sickle cell disease.

Authors:  Shruti Chaturvedi; Michael R DeBaun
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-28       Impact factor: 12.779

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.